0 316

Cited 3 times in

Efficacy and safety of pegylated interferon base treatment in patients with chronic hepatitis C on dialysis

Authors
 Sang Bong Ahn  ;  Dae Won Jun  ;  Sang Gyune Kim  ;  Sae Hwan Lee  ;  Hyun Phil Shin  ;  Won Hyeok Choe  ;  Ja Kyung Kim  ;  Kyu Sik Jung  ;  Do Young Kim  ;  Jae-Jun Shim  ;  Soo Young Park  ;  Yeon Seok Seo  ;  Won Kim  ;  Jae Il Chung 
Citation
 European Journal of Internal Medicine, Vol.26(4) : 292-296, 2015 
Journal Title
 European Journal of Internal Medicine 
ISSN
 0953-6205 
Issue Date
2015
MeSH
Adult ; Anemia/blood ; Antiviral Agents/administration & dosage* ; Antiviral Agents/adverse effects ; Drug Therapy, Combination ; Female ; Genotype ; Hepacivirus/genetics ; Hepatitis C, Chronic/therapy* ; Humans ; Interferon-alpha/administration & dosage* ; Interferon-alpha/adverse effects ; Kidney Failure, Chronic/therapy* ; Male ; Middle Aged ; Neutropenia/blood ; Patient Dropouts ; Polyethylene Glycols/administration & dosage* ; Polyethylene Glycols/adverse effects ; Recombinant Proteins/administration & dosage ; Recombinant Proteins/adverse effects ; Renal Dialysis* ; Republic of Korea ; Retrospective Studies ; Ribavirin/administration & dosage ; Treatment Outcome
Keywords
Dialysis ; Hepatitis C ; Pegylated interferon ; Renal insufficiency
Abstract
INTRODUCTION: Patients with chronic hepatitis C (CHC) and end-stage renal disease (ESRD) on dialysis are difficult to treat and show higher dropout rates during treatment. The aim of this study was to analyze the treatment outcomes in patients with CHC and underlying end-stage renal disease on dialysis in Korea. METHODS: A retrospective multi-center study of 35 patients with CHC and underlying ESRD on regular dialysis from 13 centers were analyzed. We investigated the tolerability and efficacy of pegylated interferon therapy with or without ribavirin on dialysis patients. RESULTS: Twenty patients (57%) were genotype 1. Sixteen patients (46%) were treated with pegylated interferon monotherapy. Nineteen patients (54%) were treated with pegylated interferon and ribavirin. The overall sustained virological response (SVR) rate was 65.7% in all subjects. Thirteen patients (37%) dropped out before completion of treatment, and six patients (46.2%) showed SVR despite premature termination of treatment. Twenty patients (90.9%) achieved SVR among the 22 patients who completed the scheduled course. The most common side effects were anemia and neutropenia. The patients receiving ribavirin treatment showed a higher dropout rate (52.6% vs. 18.8%, p=0.04) and higher SVR rate (68.4% vs. 62.5%, p=0.07) compared to the pegylated interferon mono-treatment group. CONCLUSIONS: The difficulty in treating HCV patients with ESRD was attributed to higher dropout rate. However, despite the high dropout rate (37%), the SVR rate in genotype 1 was 65% and in genotypes 2 and 3 was 66%. Patients who completed the treatment showed a high SVR rate of 89.5%.
DOI
10.1016/j.ejim.2015.03.011
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Do Young(김도영)
Kim, Ja Kyung(김자경) ORCID logo https://orcid.org/0000-0001-5025-6846
Jung, Kyu Sik(정규식)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/140100
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse